Novo Nordisk lowers sales outlook, class action lawsuit filed.

• Novo Nordisk sued for securities fraud • Class action filed in New York • Investors must contact Danielle Peyton by September 30, 2025 • Complaint available at pomerantzlaw.com • Company lowered sales outlook on July 29, 2025

Novo Nordisk A/S (NYSE: NVO), a Danish pharmaceutical company, is facing a class action lawsuit alleging securities fraud. The lawsuit, filed by Pomerantz LLP, claims that the company and certain of its officers and/or directors engaged in unlawful business practices. Investors who purchased or otherwise acquired Novo Nordisk securities during the class period are advised to contact Danielle Peyton at Pomerantz LLP for further information [1].

The class action lawsuit comes on the heels of Novo Nordisk significantly lowering its sales outlook for 2025 on July 29, 2025. The company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition" [1]. This news led to a significant drop in Novo Nordisk's American Depositary Receipt (ADR) price, falling $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025 [1].

Investors are encouraged to contact Danielle Peyton by September 30, 2025, to request the Court to appoint them as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com [1].

Novo Nordisk's recent setback can be attributed to weaker-than-expected momentum for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, especially in the U.S. obesity market. Despite the FDA ending its compounding grace period in May 2025, the company reported that illegal sales of counterfeit semaglutide persist under the pretext of personalization, hampering Wegovy’s uptake [3]. Market expansion has lagged, and competition in the GLP-1 obesity segment has intensified, particularly from Eli Lilly (LLY) [3].

Despite these challenges, Novo Nordisk's stock has shown a modest recovery in August, gaining 5.8% [3]. The company is actively pursuing litigation and regulatory action to protect patients and market share. Novo Nordisk is also making progress with its pipeline, which includes several new candidates for diabetes and obesity, and has strong fundamentals. The untapped nature of the obesity market presents significant upside potential for the stock [3].

References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-a-s-of-class-ac-ce7c51dfda8af023
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-novo-nordisk-as-of-class-action-lawsuit-and-upcoming-deadlines---nvo-302527374.html
[3] https://finance.yahoo.com/news/novo-nordisk-rises-6-far-144700907.html